Severe anaphylaxis caused by intravenous anti-cancer drugs

Severe anaphylaxis caused by intravenous anti-cancer drugs - Anti-cancer Drugs & Severe Anaphylaxis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042887

Enrollment

5000

Registered

2021-01-03

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Anaphylaxis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All outpatients and in patients who underwent intravenous chemotherapy for any malignancy from January 1st, 2013 to October 30th, 2020

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
incidence of severe anaphylaxis that was caused by anti-cancer medications	—

Secondary

Measure	Time frame
high-risk situation	—

Countries

Japan

Contacts

Public ContactNobuyuki Horita

Yokohama City University Ethical Guidelines for Medical and Health Research Involving Human Subjects

horitano@yokohama-cu.ac.jp045-787-2800

Outcome results